Exact Sciences Corporation
EXAS
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for breast, prostate, and colon cancers; Oncotype Testā¦ read more
Healthcare
Diagnostics & Research
24 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$53.30
Price-0.96%
-$0.51
1Y
Price
Market Cap
$10.090b
Large
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financials Overview
Key metrics over the past few years+8.0%
EBITDA Margin-0.1%
Net Profit Margin+5.8%
Free Cash Flow MarginRevenue
$2.940b
+6.6%
1y CAGR+12.3%
3y CAGR+13.7%
5y CAGREarnings
-$1.005b
+2.3%
1y CAGR-111.5%
3y CAGR-84.8%
5y CAGREPS
-$5.43
+2.9%
1y CAGR-107.9%
3y CAGR-81.4%
5y CAGRBook Value
$2.469b
$5.797b
Assets$3.328b
Liabilities$2.521b
DebtDebt to Assets
43.5%
-3.1x
Debt to EBITDAFree Cash Flow
$169.618m
+127.5%
1y CAGR+122.8%
3y CAGR+71.1%
5y CAGRFinancial Reports
Earnings and other important metrics. Amounts in USD.No items found.
Press Releases
Statements and updates from the company